453 related articles for article (PubMed ID: 18841250)
1. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
2. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
6. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
[TBL] [Abstract][Full Text] [Related]
7. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
8. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
11. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
12. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone.
Sporn MB; Hong WK
Cancer Prev Res (Phila); 2008 Jun; 1(1):9-11. PubMed ID: 19138930
[No Abstract] [Full Text] [Related]
13. A randomized trial of aspirin to prevent colorectal adenomas.
Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
15. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
[TBL] [Abstract][Full Text] [Related]
16. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
Benamouzig R; Uzzan B; Deyra J; Martin A; Girard B; Little J; Chaussade S;
Gut; 2012 Feb; 61(2):255-61. PubMed ID: 21890814
[TBL] [Abstract][Full Text] [Related]
17. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
Baron JA; Beach M; Mandel JS; van Stolk RU; Haile RW; Sandler RS; Rothstein R; Summers RW; Snover DC; Beck GJ; Bond JH; Greenberg ER
N Engl J Med; 1999 Jan; 340(2):101-7. PubMed ID: 9887161
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
